Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Not bad at all ,This is what we needed .
It is going to run and very fast soon !!
VD talking to him self again !! CVSI LONG AND GETTING SO MUCH MORE STRONGER !!
I am telling you People you are looking at a GIFT HORSE right in the a$$, so you better buy as much of this CVSI stock as you can because this horse is getting ready to run, and the last thing your going to see is the a$$ of this horse going across the finish line !! This stock is a Derby winner !! You got to get in now , MHO
Ok People you are looking at a GIFT HORSE right in the A$$, so you better buy as much of this CVSI stock as you can because this horse is getting ready to run, and the last thing your going to see is the A$$ of this horse going across the finish line !! This stock is a Derby winner !!
Ok People you are looking at a GIFT HORSE right in the A$$, so you better buy as much of this CVSI stock as you can because this horse is getting ready to run, and the last thing your going to see is the A$$ of this horse going across the finish line !! This stock is a Derby winner !!
We know which one it is don't we !
We know witch one it is !
Never fails !!
Hey i am losing too if i sell right now my average cost is 3.99 a share so i have been buying more to average down my cost in hopes of not losing all my money. I am in over $148000 right now like you are , I am in this to the end and i hope it is not end of my moneys . CVSI LONG
Do not sale it you will be sorry if you do TIMO
You do not lose unless you were crazy enough to sale !!
Ok People you are looking at a GIFT HORSE right in the a$$, so you better buy as much of this CVSI stock as you can because this horse is getting ready to run, and the last thing your going to see is his a$$ of this horse going across the finish line !! This stock is a Derby winner !!
OK People I am telling you,you are looking at a GIFT HORSE right in the ass, so you better buy as much of this stock as you can because this horse is getting ready to run and when it takes off his ass is going to be the last thing you see as it goes across the finish line !! This stock is a Derby winner !!
People you are looking at a GIFT HORSE right in the ass, so you better buy as much of this stock as you can because this horse is getting ready to run !! This stock is a Derby winner !!
CNN aired that ,HANG ON I BE RIGHT BACK got to go buy more CVSI ,Because everything CNN says is the total opposite in IMO .. STATE YOUR FACTS ONLY on this board !
CNN aired that HANG ON I got to go buy more CVSI because everything CNN says is the total opposite , BE RIGHT BACK GOT TO GET MORE CVSI !
CNN FAKE NEWS !!
Yes it is all down .
Power hour is here , This is going to get back over $2.05 OR $2.10 a share .
KH just remember it is the same company it was six months ago, but it is stronger and fundamentally sound ! It will come back up in price in time . I just hope it is not a long time !
KH just remember it is the same company it was six months ago, but it is stronger and fundamentally sound ! It will come back up in price in time . I just hope it is not a long time !
Yes it is , it should help us , all of us . I hope !!!!!
Yes the House passed the Safe banking act today . This is a great start ,now we need the FDA to get off their ass and get to work and do their JOB !!
CV Sciences, Inc. Launches Seven New Body Care Hemp CBD Products at Natural Products Expo East
BY GlobeNewswire
— 8:45 AM ET 09/24/2019
SAN DIEGO, Sept. 24, 2019 (GLOBE NEWSWIRE) -- CV Sciences, Inc. ( CVSI
Loading...
Loading...
) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, has announced the expansion of its industry-dominating brand, PlusCBD™ Oil, with the launch of seven new body care products at Natural Products Expo East.
“We are dedicated to offering the highest quality line of non-GMO full spectrum hemp CBD products in the industry,” said Joseph Dowling, Chief Executive Officer of CV Sciences ( CVSI
Loading...
Loading...
). “Our seven new body care products continue to deliver on this promise and offer innovative solutions to those seeking alternatives to traditional body care.”
Each body care product is US Hemp Authority Certified and is free from gluten, artificial dyes and fragrances, phthalates, sulfates, parabens or PEGs. All products are also non-GMO and are not tested on animals. Products will be available starting in November at all retailers where PlusCBD Oil™ is available and will include:
PlusCBD™ Oil Raw Hemp Balm, Travel Size - Infused with 25mg of skin-balancing CBDA and CBD from eco-friendly agricultural hemp, PlusCBD™ Oil Hemp Balm promotes clear skin in a convenient, travel-size balm.
PlusCBD™ Oil Gold Hemp Balm, Travel Size - Infused with 45mg of concentrated CBD from eco-friendly agricultural hemp, PlusCBD™ Oil Hemp Balm supports healthy skin in a convenient, travel-size balm.
PlusCBD™ Oil Gold Hemp Stick, Hands-Free - Infused with 150mg of concentrated CBD from eco-friendly agricultural hemp, including nourishing calendula and hydrating shea butter, PlusCBD™ Oil Hemp Stick supports healthy looking skin in a convenient, hands-free balm.
PlusCBD™ Oil Gold Hemp Skin Serum, Lavender Scent - Infused with 50mg of concentrated CBD from eco-friendly agricultural hemp, PlusCBD™ Oil Hemp Skin Serum moisturizes with jojoba, avocado, and coconut oils, and hydrates with hyaluronic acid.
PlusCBD™ Oil Gold Hemp Body Lotion, Lavender Scent - Infused with 200mg of concentrated CBD from eco-friendly agricultural hemp, hydrating shea butter and nourishing argan oil, PlusCBD™ Oil Hemp Body Lotion promotes softer skin.
PlusCBD™ Oil Gold Hemp Body Lotion, Grapefruit Scent - Infused with 200mg of concentrated CBD from eco-friendly agricultural hemp, hydrating shea butter and nourishing argan oil, PlusCBD™ Oil Hemp Body Lotion promotes softer skin.
PlusCBD™ Oil Gold Body Cream, Lavender Scent - Infused with 150mg of concentrated CBD from eco-friendly agricultural hemp, hydrating marula seed oil, and nourishing argan oil, PlusCBD™ Oil Hemp Body Cream supports healthy looking skin.
In addition to the launch of these products, CV Sciences ( CVSI
Loading...
Loading...
) garnered the “"NEXTY Consumer Choice Award" in the Supplement Category for the Company’s PlusCBD™ Oil Total Plant Complex Peppermint Spray. Bestowed each year at Natural Products Expo East and West, the NEXTY Awards recognize natural products that eclipse others within their category in terms of innovation, inspiration, and integrity.
About CV Sciences, Inc. ( CVSI
Loading...
Loading...
)
CV Sciences, Inc. ( CVSI
Loading...
Loading...
) operates two distinct business segments: a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors; and a drug development division focused on developing and commercializing CBD-based novel therapeutics utilizing CBD. The Company’s PlusCBD™ Oil is the top-selling brand of hemp-derived CBD on the market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. CV Sciences’ state-of-the-art facility follows all guidelines for Good Manufacturing Practices (GMP) and the Company’s full spectrum hemp extracts are processed, produced, and tested throughout the manufacturing process to confirm the cannabinoid content meets strict company standards. With a commitment to science, PlusCBD™ Oil was the first hemp CBD supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status.CV Sciences, Inc. has primary offices and facilities in San Diego, California. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.
CONTACT INFORMATION:
Investor Contact:
ICR
Scott Van Winkle
617-956-6736
scott.vanwinkle@icrinc.com
Media Contact:
ICR
Cory Ziskind
646-277-1232
cory.ziskind@icrinc.com
Image: CV_Logo_Horizontal_black_300dpi (1).png
Source: CV Sciences, Inc. ( CVSI )
I understand ,, i truly am in the same boat as you are , lets hope this stock comes back and fast !!!!!!!!!!!.
Look i have 27,000 shares just about what you have ,and i am not going to give them up when we all know CVSI is the same as it was 3 months ago but even stronger now . I just cant find a real reason to bale out now !!
I will be here to see , I am long .
Same here KH i am here to the end winner take all !!!
I am keeping my shares, i will lose all before i sell mine! CVSI LONG AND STRONG !
And without any GATORS IN IT just for you !
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): September 17, 2019
CV SCIENCES, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
000-54677
(Commission File Number)
80-0944970
(I.R.S. Employer Identification No.)
10070 Barnes Canyon Road
San Diego, California 92121
(Address of principal executive offices)
(866) 290-2157
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
? Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
? Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
? Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
? Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of exchange on which registered
N/A
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company ?
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ?
Item 8.01
Other Events
On September 17, 2019, CV Sciences, Inc. (the “Company”) was informed by the United States Patent and Trademark Office (the “USPTO”) that the Patent Trial and Appeal Board (“PTAB”) had rejected the Company’s appeal to overturn the Examiner’s decision to deny certain claims made within the Company’s patent application (the “Subsequent Notice”), U.S. Patent Application No. 15/426,617 (the “’617 Application”). The Company intends to file a Request for Continued Examination (RCE) of the ‘617 Application, in order to continue to seek and obtain patent protection for the inventions described in the ‘617 Application. The Company believes that at least certain inventions described in the ‘617 Application are entitled to patent protection based on the record that was before the PTAB.
The information set forth in this Current Report on Form 8-K (“Current Report”) contains forward-looking statements. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are based upon assumptions as to future events that may not prove to be accurate. Actual outcomes and results may differ materially from what is expressed in these forward-looking statements.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
99.1 Press release, dated September 19, 2019
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: September 19, 2019
CV SCIENCES, INC.
By: /s/ Joseph Dowling
Joseph Dowling
Chief Executive Officer
Exhibit 99.1
CV SCIENCES, INC. ANNOUNCES PLANS TO FILE REQUEST FOR CONTINUED EXAMINATION OF ITS US PATENT APPLICATION
SAN DIEGO, September 19, 2019 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its intention to file for a Request of Continued Examination (“RCE”) of its patent application No. 15/426,617 with the US Patent Trademark Office (“USPTO”), titled Pharmaceutical Formulations Containing Cannabidiol and Nicotine For Treating Smokeless Tobacco Addiction. The intent to file an RCE follows USPTO notifying the Company that the Patent Trial and Appeal Board (“PTAB”) had rejected the Company’s appeal to overturn the examiner’s decision to deny certain claims made within the Company’s patent application.
“While the USPTO decision is disappointing, it’s important to recognize that this is not the end of the process and we plan to request continued examination,” said Joseph Dowling, Chief Executive Officer of CV Sciences. “We remain confident in protecting our intellectual property surrounding these formulations and our ability to commercialize this invention, which we believe can provide a solution to a lingering epidemic in smokeless tobacco use. We will continue to focus on developing products that improve the quality of life of our customers.”
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors; and a drug development division focused on developing and commercializing CBD-based novel therapeutics utilizing CBD. The Company’s PlusCBD™ Oil is the top-selling brand of hemp-derived CBD on the market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. CV Sciences’ state-of-the-art facility follows all guidelines for Good Manufacturing Practices (GMP) and the Company’s full spectrum hemp extracts are processed, produced, and tested throughout the manufacturing process to confirm the cannabinoid content meets strict company standards. With a commitment to science, PlusCBD™ Oil was the first hemp CBD supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status.CV Sciences, Inc. has primary offices and facilities in San Diego, California. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.
CONTACT INFORMATION:
Investor Contact:
ICR
Scott Van Winkle
617-956-6736
scott.vanwinkle@icrinc.com
Media Contact:
ICR
Cory Ziskind
646-277-1232
cory.ziskind@icrinc.com
I got me 500 more today at 2.77
OMG What is going on here ? DID WE GET ANOTHER SHORT ATTACK !!
Amen to that CMC
He is a BASHER there is none , CVSI LONG !!!!!!!!!!!
Yep it is crazy ,,,
CV Sciences, Inc. Wins 2019 NEXTY Award
BY GlobeNewswire
— 8:45 AM ET 09/17/2019
Company’s industry-dominating hemp extract brand, PlusCBD Oil™, wins Consumer Choice Award at Natural Products Expo East
SAN DIEGO, Sept. 17, 2019 (GLOBE NEWSWIRE) -- CV Sciences, Inc. ( CVSI
Loading...
Loading...
) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, announced today that it received the “NEXTY Consumer Choice Award” in the Supplement Category for the Company’s PlusCBD™ Oil Total Plant Complex Peppermint Spray.
Bestowed each year at Natural Products Expo East and West, the NEXTY Awards recognize natural products that eclipse others within their category in terms of innovation, inspiration, and integrity. All product candidates are evaluated via a rigorous submission and two-tiered judging process, and the winning products are selected based on targeted consumer feedback from 1,000 consumers who sample and score the products.
“Consumers choose and trust PlusCBD Oil because of our quality, purity and consistency. We offer the highest quality line of gluten-free, non-GMO full spectrum hemp CBD products in the industry and we’ve built our reputation on product purity and fundamentally sound research practices,” said Joseph Dowling, Chief Executive Officer of CV Sciences ( CVSI
Loading...
Loading...
). “We are proud to be recognized by consumers as their favorite supplement, especially by those who are new to CBD.”
PlusCBD Oil Sprays are a convenient and portable option for those who take CBD oil daily and are available in three flavor options—Peppermint, Café Mocha and unflavored. Made with CBD derived from agricultural hemp, a renewable resource, PlusCBD Oil Sprays also contain naturally occurring Vitamin E, fatty acids, and other beneficial plant compounds.
About CV Sciences, Inc. ( CVSI
Loading...
Loading...
) CV Sciences, Inc. ( CVSI
Loading...
Loading...
) operates two distinct business segments: a consumer product division focused on manufacturing, marketing and selling hemp-derived CBD products to a range of market sectors; and a drug development division focused on developing and commercializing novel therapeutics utilizing CBD. The Company’s PlusCBD™ Oil is the top-selling brand of hemp-derived CBD on the market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. CV Sciences’ state-of-the-art facility follows all guidelines for Good Manufacturing Practices (GMP) and the Company’s full spectrum hemp extracts are processed, produced, and tested throughout the manufacturing process to confirm the cannabinoid content meets strict company quality standards. With a commitment to science, PlusCBD™ Oil’s benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. PlusCBD™ Oil was the first hemp-derived CBD supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. CV Sciences, Inc. ( CVSI
Loading...
Loading...
) has primary offices and facilities in San Diego, California. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.
Investor Contact:
ICR
Scott Van Winkle
617-956-6736
scott.vanwinkle@icrinc.com
Media Contact:
ICR
Cory Ziskind
646-277-1232
cory.ziskind@icrinc.com
Image: CV_Logo_Horizontal_black_300dpi (1).png
Source: CV Sciences, Inc. ( CVSI
Loading...
Loading...
)
This is good news right , From the way i am reading it ?
Show me that news please